Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 285

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 285
---
 vests and becomes exercisable in thirty-six (36) substantially equal monthly installments thereafter, in each case, subject to Mr. Prensky continuing to have a service relationship (as
defined in the 2023 Plan) with us through each such date. Mr. Prensky was also entitled to certain severance benefits, pursuant to the Prensky Employment Agreement. In November 2024, we entered into a separation agreement with Mr. Prensky,
the terms of which are described below under “—Potential Payments Upon Termination or Change in Control.”

Roger Sawhney

In June 2024, we entered into an executive employment agreement with Roger Sawhney, our former Chief Financial Officer, who
commenced employment on June 21, 2024, or the Sawhney Employment Agreement. The Sawhney Employment Agreement provided for an annual base salary of $410,000 per year. Pursuant to the Sawhney Employment Agreement, Mr. Sawhney was eligible to
receive an annual performance cash bonus with a target bonus opportunity equal to 40% of his base salary, as adjusted from time to time, based on the achievement of corporate and individual objectives and milestones established by our board of
directors. Additionally, the Sawhney Employment Agreement provided for the grant of an option to purchase 34,065 shares of our common stock, at an exercise price of $41.84 per share, whereby 25% of the option would have vested and become exercisable
upon the first anniversary of the effective date of the Sawhney Employment Agreement, with the remainder vesting and becoming exercisable in thirty-six (36) substantially equal monthly installments
thereafter, subject to Mr. Sawhney continuing to have a service relationship (as defined in the 2023 Plan) with us through each such date. Mr. Sawhney was also entitled to certain severance benefits, the terms of which are described below
under “—Potential Payments Upon Termination or Change in Control.” In May 2025, we entered into a separation agreement with Mr. Sawhney, the terms of which are described below under “—Potential Payments Upon
Termination or Change in Control.”

Anna Eramo, M.D.

In August 2023, we entered into an executive employment agreement with Anna Eramo, M.D., our Chief Medical Officer, or the Eramo Employment
Agreement. The Eramo Employment Agreement provides for an annual base salary of $